Abstract 195P
Background
The systemic immunological effects of combining anti-CTLA4 therapy with PD-(L)1 blockade remain incompletely characterized, despite the widespread use of this combination in treating various solid tumors. We investigated the additive impact of anti-CTLA4 on peripheral immune signatures in patients undergoing PD-(L)1 blockade, using serial blood samples from a cohort of patients receiving checkpoint inhibitor therapy for advanced solid tumors.
Methods
We prospectively collected serial blood specimens from adult patients receiving treatment with anti-PD(L)1 alone or in combination with anti-CTLA4 therapy for advanced, unresectable solid tumors at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. We performed in-parallel analysis of peripheral blood mononuclear cells (PBMC) using Cytometry by Time-of-Flight (CyTOF), and plasma cytokines using Luminex immunoassay on specimens collected at baseline and early on treatment (month 1 or 2).
Results
Our study cohort included 109 patients [anti-PD(L)1 alone, n=58, in combination with anti-CTLA4, n=51]. As compared to single-agent anti-PD(L)1, combination therapy was associated with a greater expansion of CD4+ helper subsets, including Th17 (adjusted p=0.039) and Treg (adjusted p=0.018) after multivariable and multiple testing adjustment. In patients receiving anti-CTLA4, Th17 populations demonstrated an acquired non-classical Th1-like phenotype characterized by upregulation of the Th1-related transcription factor T-BET (p=0.04). Assessment of the peripheral cytokine signatures showed an increase in Th1-associated cytokines in combination ICI recipients, particularly the IFNg inducible cytokines MIG (adjusted p=0.021), IP-10 (adjusted p=0.021).
Conclusions
Our results confirm prior reports that anti-CTLA4 therapy is associated with augmentation of Th17 cell subsets but show that anti-CTLA4 may also contribute to a Th1-like program as a result of lineage plasticity.
Legal entity responsible for the study
Johns Hopkins, Genentech/Roche.
Funding
F. Hoffmann-La Roche Ltd.
Disclosure
M. Baretti: Financial Interests, Personal, Other, Personal Fees: AstraZeneca, Incyte. G.S. Chandler: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche. R. Mohindra: Financial Interests, Personal, Full or part-time Employment: F. Hoffmann-La Roche Ltd.; Financial Interests, Personal, Stocks/Shares: F. Hoffmann-La Roche Ltd. E.M. Jaffee: Financial Interests, Personal, Other: Abmeta; Financial Interests, Personal, Other, Personal Fees: Genocea, Achilles, DragonFly, Candel Therapeutics, Carta, NextCure; Financial Interests, Personal and Institutional, Research Grant: Lustgarten, Genentech, Break Through Cancer; Financial Interests, Institutional, Research Grant: AstraZeneca. W.J. Ho: Financial Interests, Personal, Royalties: Rodeo/Amgen; Financial Interests, Personal and Institutional, Research Grant: Sanofi, NeoTX, Circle Pharma; Financial Interests, Personal, Speaker, Consultant, Advisor: Exelixis. M. Yarchoan: Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca, Exelixis, Genentech, Replimune, Hepion, Lantheus; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, Exelixis, Genentech, Incyte; Financial Interests, Personal, Officer: Adventris Pharmaceuticals. All other authors have declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract